NurExone Biologic Ratios and Metrics

Market cap in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Apr '26 Apr 10, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Cap	62	44	14	17	-	-
Market Cap Growth	27.41%	211.83%	-16.60%	-	-	-
Enterprise Value	60.41	42.9	13.35	13.55	0	0
Last Close Price	0.65	0.62	0.29	0.39	-	-
PE Ratio	-	5.58	2.72	1.34	-	-
PB Ratio	30.39	17.35	56.16	5.93	-	-
P/TBV Ratio	33.27	22.92	68.98	7.08	-	-
P/FCF Ratio	-	-5.52	-3.47	-3.19	-	-
P/OCF Ratio	-	-6.25	-3.61	-3.23	-	-
EV/EBITDA Ratio	-	-6.07	-2.78	-1.31	-	-
EV/EBIT Ratio	-	-5.97	-2.76	-1.31	-	-
EV/FCF Ratio	-8.40	-5.40	-3.29	-2.56	-	-
Debt / Equity Ratio	0.05	0.02	0.01	0.01	0.89	0
Debt / EBITDA Ratio	-0.01	-0.01	0.00	0.00	-0.61	-
Debt / FCF Ratio	-0.01	-0.01	0.00	0.00	-0.85	-
Net Debt / Equity Ratio	-0.62	-0.38	-2.85	-1.17	-0.99	0.10
Net Debt / EBITDA Ratio	0.14	0.14	0.15	0.32	0.68	0.11
Net Debt / FCF Ratio	0.18	0.12	0.18	0.63	0.95	0.09
Quick Ratio	1.28	2.49	0.39	4.37	1.73	0.09
Current Ratio	1.33	4.11	1.04	4.46	1.74	0.18
Return on Equity (ROE)	-406.15%	-517.23%	-318.51%	-499.18%	-296.35%	40.31%
Return on Assets (ROA)	-254.45%	-217.26%	-147.34%	-270.66%	-120.21%	-312.09%
Return on Invested Capital (ROIC)	-603.73%	-425.21%	-987.04%	-380950.00%	-1513.18%	138.24%
Return on Capital Employed (ROCE)	-338.23%	-434.62%	-298.17%	-448.70%	-300.65%	119.72%
Earnings Yield	-14.76%	17.91%	36.82%	74.48%	-	-
FCF Yield	-11.66%	-18.12%	-28.84%	-31.38%	-	-
Buyback Yield / Dilution	-27.20%	-46.27%	-18.52%	-129.36%	-548.74%	-2.55%
Total Shareholder Return	-27.20%	-46.27%	-18.52%	-129.36%	-548.74%	-2.55%

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.